The DOI matches its Crossref record; 294 of the 294 references it cites were found in a registry or an index.
Metabolic reprogramming in cancer: Mechanisms and therapeutics
Open accessAbstract
Cancer cells characterized by uncontrolled growth and proliferation require altered metabolic processes to maintain this characteristic. Metabolic reprogramming is a process mediated by various factors, including oncogenes, tumor suppressor genes, changes in growth factors, and tumor–host cell interactions, which help to meet the needs of cancer cell anabolism and promote tumor development. Metabolic reprogramming in tumor cells is dynamically variable, depending on the tumor type and microenvironment, and reprogramming involves multiple metabolic pathways. These metabolic pathways have complex mechanisms and involve the coordination of various signaling molecules, proteins, and enzymes, which increases the resistance of tumor cells to traditional antitumor therapies. With the development of cancer therapies, metabolic reprogramming has been recognized as a new therapeutic target for metabolic changes in tumor cells. Therefore, understanding how multiple metabolic pathways in cancer cells change can provide a reference for the development of new therapies for tumor treatment. Here, we systemically reviewed the metabolic changes and their alteration factors, together with the current tumor regulation treatments and other possible treatments that are still under investigation. Continuous efforts are needed to further explore the mechanism of cancer metabolism reprogramming and corresponding metabolic treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 201–294 of 294
Acetate Fuels the Cancer Engine
Lyssiotis, C. A., & Cantley, L. C. (2014) · Cell · doi:10.1016/j.cell.2014.12.009 · Cited by 98
Targeting LKB1 in Cancer – Exposing and Exploiting Vulnerabilities
Momcilovic, M., & Shackelford, D. B. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.261 · Cited by 97
Physiological functions of the pentose phosphate pathway
Wood, T. (1986) · Cell Biochemistry and Function · doi:10.1002/cbf.290040403 · Cited by 97
Molecular Mechanisms and Cellular Contribution from Lung Fibrosis to Lung Cancer Development
Samarelli, A. V., Masciale, V., Aramini, B., Coló, G. P., Tonelli, R., Marchioni, A., Bruzzi, G., Gozzi, F., Andrisani, D., Castaniere, I., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212179 · Cited by 97
Orlistat in the treatment of obesity
Ballinger, A. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.4.841 · Cited by 94
Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockadePreprint
Lue, H.-W., Podolak, J., Kolahi, K. S., Cheng, L. C., Rao, S. A. M., Garg, D., Xue, C.-H., Rantala, J., Tyner, J. W., Thornburg, K. L. R., et al. (2017) · Genes & Development · doi:10.1101/gad.305292.117 · Cited by 92
Structure-Based Design of Potent and Selective Inhibitors of the Metabolic Kinase PFKFB3
Boyd, S., Brookfield, J. L., Critchlow, S. E., Cumming, I. A., Curtis, N. J., Debreczeni, J. E., Degorce, S. L., Donald, C. S., Evans, N. J., Groombridge, S. D., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00352 · Cited by 91
Non-coding RNAs in the reprogramming of glucose metabolism in cancer
Shankaraiah, R. C., Veronese, A., Sabbioni, S., & Negrini, M. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.048 · Cited by 91
de la Fuente, M. I., Colman, H., Rosenthal, M. A., Tine, B. A. V., Levacic, D., Walbert, T., Gan, H. K., Vieito, M., Milhem, M. M., Lipford, K., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac139 · Cited by 91
Re-Discovery of Pyrimidine Salvage as Target in Cancer Therapy
Walter, M., & Herr, P. (2022) · Cells · doi:10.3390/cells11040739 · Cited by 90
Bruce, J. Y., Eickhoff, J. C., Пили, Р., Logan, T. F., Carducci, M. A., Arnott, J., Treston, A. M., Wilding, G., & Liu, G. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9618-9 · Cited by 88
Robert, C., Flaherty, K. T., Nathan, P., Hersey, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Mohr, P., Hassel, J. C., Rutkowski, P. L., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.015 · Cited by 88
Wong, C. C., Au, S. L., Tse, A. P., Xu, M., Lai, R. K., Chiu, D. K., Wei, L. L., Fan, D. N.-Y., Tsang, F. H., Lo, R. C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115036 · Cited by 87
The natural product carolacton inhibits folate-dependent C1 metabolism by targeting FolD/MTHFD
Fu, C., Sikandar, A., Donner, J., Zaburannyi, N., Herrmann, J. E., Reck, M., Wagner‐Döbler, I., Koehnke, J., & Müller, R. (2017) · Nature Communications · doi:10.1038/s41467-017-01671-5 · Cited by 86
Li, W., Hao, J., Zhang, L., Cheng, Z., Deng, X., & Shu, G. (2017) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.7b02120 · Cited by 84
Pancreatic cancers rely on a novel glutamine metabolism pathway to maintain redox balance
Lyssiotis, C. A., Son, J., Cantley, L. C., & Kimmelman, A. C. (2013) · Cell Cycle · doi:10.4161/cc.25307 · Cited by 83
Limits of aerobic metabolism in cancer cells
Fernández-de-Cossio-Díaz, J., & Vázquez, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-14071-y · Cited by 82
Liu, B., Pan, S., Xiao, Y., Liu, Q., Xu, J., & Li, J. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1367-9 · Cited by 80
Novel inhibitors of basal glucose transport as potential anticancer agents
Zhang, W., Liu, Y., Chen, X., & Bergmeier, S. C. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.02.027 · Cited by 78
Enhanced antitumor activity of cerulenin combined with oxaliplatin in human colon cancer cells
Shiragami, R., Murata, S., Kosugi, C., Tezuka, T., Yamazaki, M., Hirano, A., Yoshimura, Y., Suzuki, M., Shuto, K., & Koda, K. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1978 · Cited by 76
The Immune Consequences of Lactate in the Tumor Microenvironment
Harmon, C., O’Farrelly, C., & Robinson, M. W. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43093-1_7 · Cited by 74
FOXM1D potentiates PKM2‐mediated tumor glycolysis and angiogenesis
Zhang, W., Zhang, X., Huang, S., Chen, J., Ding, P., Wang, Q., Li, L., Lv, X., Li, L., Zhang, P., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12879 · Cited by 74
Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2
Borodovsky, A., Seltzer, M. J., & Riggins, G. J. (2011) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32834d816a · Cited by 71
Curcumin directly inhibits the transport activity of GLUT1
Gunnink, L. K., Alabi, O. D., Kuiper, B. D., Gunnink, S. M., Schuiteman, S. J., Rylaarsdam, L. E., Hamilton, K. E., Wrobel, K. E., & Louters, L. L. (2016) · Biochimie · doi:10.1016/j.biochi.2016.03.014 · Cited by 70
Gan, L., Xiu, R., Ren, P., Yue, M., Su, H., Guo, G., Xiao, D., Yu, J., Jiang, H., Liu, H., et al. (2015) · Oncogene · doi:10.1038/onc.2015.360 · Cited by 69
Powell, S. F., Mazurczak, M. A., Dib, E. G., Bleeker, J. S., Geeraerts, L., Tinguely, M., Lohr, M. M., McGraw, S. C., Jensen, A. W., Ellison, C. A., et al. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01235-5 · Cited by 69
Bacterial l ‐asparaginases for cancer therapy: Current knowledge and future perspectives
Ghasemian, A., AL-Marzoqi, A. H., Al-Abodi, H. R., Alghanimi, Y. K., Kadhum, S. A., Mostafavi, S. K. S., & Fattahi, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28563 · Cited by 68
Li, E.-Q., Zhao, W., Zhang, C., Qin, L.-Z., Liu, S., Feng, Z., Wen, X., & Chen, C. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105010 · Cited by 68
Regulation of Vascular Endothelial Growth Factor Receptors by Rb and E2F1: Role of Acetylation
Pillai, S., Kovacs, M. A., & Chellappan, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0501 · Cited by 65
Han, X., Sheng, X., Jones, H. M., Jackson, A. L., Kilgore, J., Stine, J. E., Schointuch, M., Zhou, C., & Bae-Jump, V. L. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0097-x · Cited by 65
Self-citationBlagden, S. P., Hamilton, A. L., Mileshkin, L., Wong, S., Michael, A., Hall, M., Goh, J. C. H., Lisyanskaya, A. S., DeSilvio, M., Frangou, E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2277 · Cited by 65
NAD: A master regulator of transcription
Ghosh, S., George, S., Roy, U., Ramachandran, D., & Kolthur‐Seetharam, U. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.08.002 · Cited by 64
CENPE promotes lung adenocarcinoma proliferation and is directly regulated by FOXM1
Shan, L., Zhao, M., Lu, Y., Ning, H., Ouyang, C., Song, Y., Chai, W., & Shi, X. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4805 · Cited by 64
A Novel Dual AMPK Activator/mTOR Inhibitor Inhibits Thyroid Cancer Cell Growth
Plews, R. L., Yusof, A. M., Wang, C., Saji, M., Zhang, X., Chen, C., Ringel, M. D., & Phay, J. E. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1777 · Cited by 62
Zhang, Z., Li, J., Guan, D., Liang, C., Zhuo, Z., Liu, J., Lü, A., Zhang, G., & Zhang, B. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.09.014 · Cited by 62
Phase II AIDS Malignancy Consortium Trial of Topical Halofuginone in AIDS-Related Kaposi Sarcoma
Koon, H. B., Fingleton, B., Lee, J. Y., Geyer, J. T., Cesarman, E., Parise, R. A., Egorin, M. J., Dezube, B. J., Aboulafia, D. M., & Krown, S. E. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181fc0141 · Cited by 61
De novo lipogenesis represents a therapeutic target in mutant Kras non‐small cell lung cancer
Singh, A., Ruiz, C. F., Bhalla, K., Haley, J. D., Li, Q. K., Acquaah-Mensah, G. K., Montal, E. D., Sudini, K. R., Skoulidis, F., Wistuba, I. I., et al. (2018) · The FASEB Journal · doi:10.1096/fj.201800204 · Cited by 60
Liu, H., Zhang, W., Wang, K., Wang, X., Yin, F., Li, C., Wang, C., Zhao, B., Chen, Z., Zhang, J., et al. (2014) · Toxicology Letters · doi:10.1016/j.toxlet.2014.11.011 · Cited by 59
Akt inhibition promotes hexokinase 2 redistribution and glucose uptake in cancer cells
Neary, C. L., & Pastorino, J. G. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24361 · Cited by 59
Dekhne, A. S., Shah, K., Ducker, G. S., Katinas, J. M., Wong-Roushar, J., Nayeen, M. J., Doshi, A., Ning, C., Bao, X., Frühauf, J., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0037 · Cited by 59
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
Heuser, M., Palmisiano, N. D., Mantzaris, I., Mims, A. S., Dinardo, C. D., Silverman, L. R., Wang, E. S., Fiedler, W., Baldus, C. D., Schwind, S., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0996-5 · Cited by 59
Fang, Z., Jiang, C., Feng, Y., Chen, R., Lin, X., Zhang, Z., Han, L., Chen, X., Li, H., Guo, Y., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.05.016 · Cited by 58
Guan, X., & Morris, M. E. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00466-9 · Cited by 58
Peng, Y., Zhu, Y., Yin, L., Zhang, J., Wei, J., Liu, X., Liu, X., Gao, W., Jiang, K., & Miao, Y. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0500-x · Cited by 57
Tao, L., Wei, L., Liu, Y., Ding, Y., Liu, X., Zhang, X., Wang, X., Yao, Y., Lu, J., Wang, Q., et al. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.11.001 · Cited by 54
The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling
Yamashita, A. S., Rosa, M. D. C., Stumpo, V., Rais, R., Slusher, B. S., & Riggins, G. J. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa149 · Cited by 53
Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints
Xu, Y., He, L., Fu, Q., & Hu, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.759015 · Cited by 52
Lactic acidosis induces resistance to the pan-Akt inhibitor uprosertib in colon cancer cells
Barnes, E., Xu, Y., Benito, A., Herendi, L., Siskos, A., Aboagye, E. O., Nijhuis, A. M., & Keun, H. C. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0777-y · Cited by 51
Jan, C.-I., Tsai, M.-H., Chiu, C., Huang, Y., Liu, C.-J., & Chang, N. W. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.13851 · Cited by 50
Macek, P., Cliff, M. J., Embrey, K. J., Holdgate, G. A., Nissink, J. W. M., Panova, S., Waltho, J. P., & Davies, R. A. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.002709 · Cited by 50
Clinical importance of FASN in relation to HIF-1α and SREBP-1c in gastric adenocarcinoma
Ezzeddini, R., Taghikhani, M., Somi, M. H., Samadi, N., & Rasaee, M. J. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.03.056 · Cited by 49
Amith, S. R., & Fliegel, L. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.01.004 · Cited by 48
Vázquez, M. J., Leavens, W. J., Liu, R., Rodríguez, B., Read, M., Richards, S., Winegar, D. A., & Domı́nguez, J. M. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06314.x · Cited by 47
Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate
Nakano, A., Miki, H., Nakamura, S., Harada, T., Oda, A., Amou, H., Fujii, S., Kagawa, K., Takeuchi, K., Ozaki, S., et al. (2012) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-012-9412-9 · Cited by 46
Gong, J., Shen, S., Yang, Y., Qin, S., Huang, L., Zhang, H., Chen, L., Chen, Y., Li, S., She, S., et al. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3867 · Cited by 45
Lea, M. A., Guzman, Y., & desBordes, C. (2016) · PubMed · Cited by 44
Evolution of GAPDH as a druggable target of tumor glycolysis?
Ganapathy‐Kanniappan, S. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1449834 · Cited by 44
Capecitabine for the treatment of pancreatic cancer
Siddiqui, N. S., Godara, A., Byrne, M. M., & Saif, M. W. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1560422 · Cited by 44
2-Hydroxyestradiol Is a Prodrug of 2-Methoxyestradiol
Zacharia, L. C., Piché, C. A., Fielding, R. M., Holland, K. M., Allison, S. D., Dubey, R. K., & Jackson, E. K. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.062505 · Cited by 43
Oliveira, T. D., Goldhardt, T., Edelmann, M., Rogge, T., Rauch, K., Kyuchukov, N. D., Menck, K., Bleckmann, A., Kalucka, J. M., Khan, S., et al. (2021) · Cancers · doi:10.3390/cancers13051011 · Cited by 43
Prostate Cancer Cells in Different Androgen Receptor Status Employ Different Leucine Transporters
Otsuki, H., Kimura, T., Yamaga, T., Kosaka, T., Suehiro, J., & Sakurai, H. (2016) · The Prostate · doi:10.1002/pros.23263 · Cited by 42
Daneshmandi, S., Cassel, T., Higashi, R. M., Fan, T. W. ‐., & Seth, P. (2021) · eLife · doi:10.7554/elife.67476 · Cited by 42
Wang, Q., Grkovic, T., Font, J. S., Bonham, S., Pouwer, R. H., Bailey, C. G., Moran, A. M., Ryan, R. M., Rasko, J. E. J., Jormakka, M., et al. (2014) · ACS Chemical Biology · doi:10.1021/cb500120x · Cited by 40
Molecular Imaging of IGF-1R in Cancer
Sun, Y., Sun, X., & Shen, B. (2017) · Molecular Imaging · doi:10.1177/1536012117736648 · Cited by 40
Kawaguchi, K., Han, Q., Li, S., Tan, Y., Igarashi, K., Miyake, K., Kiyuna, T., Miyake, M., Chemielwski, B., Nelson, S. D., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24264 · Cited by 40
AMPK: An odyssey of a metabolic regulator, a tumor suppressor, and now a contextual oncogene
Penugurti, V., Mishra, Y. G., & Manavathi, B. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188785 · Cited by 40
IDH1-mutated relapsed or refractory AML: current challenges and future prospects
Megías‐Vericat, J. E., Ballesta‐López, O., Barragán, E., & Montesinos, P. (2019) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s177913 · Cited by 37
Amino Acid Oncometabolism and Immunomodulation of the Tumor Microenvironment in Lung Cancer
Fahrmann, J. F., Vykoukal, J. V., & Ostrin, E. J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00276 · Cited by 36
Skrypek, K., Balog, S., Eriguchi, Y., & Asahina, K. (2021) · Pancreas · doi:10.1097/mpa.0000000000001737 · Cited by 36
de Marinis, F., Rinaldi, M., Ardizzoni, A., Bruzzi, P., Pennucci, M. C., Portalone, L., DʼAprile, M., Ripanti, P., Romano, F., Belli, M., et al. (1999) · Tumori Journal · doi:10.1177/030089169908500306 · Cited by 34
Rana, R. M., Rampogu, S. D., Abid, N. B., Zeb, A., Parate, S., Lee, G., Yoon, S., Kim, Y., Kim, D. H., & Lee, K. W. (2020) · Molecules · doi:10.3390/molecules25153510 · Cited by 34
Selumetinib for the treatment of non-small cell lung cancer
Casaluce, F., Sgambato, A., Maione, P., Sacco, P. C., Santabarbara, G., & Gridelli, C. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1351543 · Cited by 33
Counteracting Action of Curcumin on High Glucose-Induced Chemoresistance in Hepatic Carcinoma Cells
Soni, V. K., Mehta, A., Ratre, Y. K., Chandra, V., Shukla, D., Kumar, A., & Vishvakarma, N. K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.738961 · Cited by 33
Liu, L., Gritz, D., & Parent, C. A. (2014) · Molecular Biology of the Cell · doi:10.1091/mbc.e14-01-0037 · Cited by 32
Identification and validation of dysregulated metabolic pathways in metastatic renal cell carcinoma
White, N. M. A., Newsted, D., Masui, O., Romaschin, A. D., Siu, K. W. M., & Yousef, G. M. (2013) · Tumor Biology · doi:10.1007/s13277-013-1245-6 · Cited by 32
Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells
Okimoto, T., Kotani, H., Iida, Y., Koyanagi, A., Tanino, R., Tsubata, Y., Isobe, T., & Harada, M. (2020) · Cancer Science · doi:10.1111/cas.14401 · Cited by 32
Zhang, J., Zhang, S., Gao, S., Ma, Y., Tan, X., Kang, Y., & Ren, W. (2020) · Cancer Management and Research · doi:10.2147/cmar.s246349 · Cited by 27
Pedersen, S. F., Flinck, M., & Pardo, L. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105209 · Cited by 27
Metabolism in the Tumor Microenvironment
Montenegro, F., & Indraccolo, S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-44518-8_1 · Cited by 26
Huang, H., Tang, J. P., Zhou, S., Yi, T., Peng, H., Shen, G., Xie, N., Huang, K., Yang, T., Wu, J., et al. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1465 · Cited by 25
Self-citationHe, W., Xu, Z., Song, D., Zhang, H., Li, B., Gao, L., Zhang, Y., Feng, Q., Yu, D., Hu, L., et al. (2020) · Life Sciences · doi:10.1016/j.lfs.2019.117249 · Cited by 25
Dalton, K. M., Lochmann, T. L., Floros, K. V., Calbert, M. L., Kurupi, R., Stein, G. T., McClanaghan, J., Murchie, E., Egan, R. K., Greninger, P., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2009620118 · Cited by 24
Wu, J., Hong, Y. K., Wu, T., Wang, J., Chen, X., Wang, Z., Cheng, B., & Xia, J. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3267 · Cited by 23
Kim, S. T., Kim, S. Y., Lee, J., Yun, S. H., Kim, H. C., Lee, W. Y., Kim, T. W., Hong, Y. S., Lim, S.-B., Baek, J. Y., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02962 · Cited by 21
PRDM3 attenuates pancreatitis and pancreatic tumorigenesis by regulating inflammatory response
Ye, J., Huang, A., Wang, H., Zhang, A. M. Y., Huang, X., Lan, Q., Sato, T., Goyama, S., Kurokawa, M., Deng, C., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2371-x · Cited by 19
Qiu, Z., Deng, W., Hong, Y.-P., Zhao, L., Li, M., Guan, Y., Su, Y.-R., Chen, C., Shi, Q., Yu, J., et al. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s282906 · Cited by 17
Nitric Oxide And Oxygen: Actions And Interactions In Health And Disease
Moncada, P. S. S. (2015) · Redox Biology · doi:10.1016/j.redox.2015.09.034 · Cited by 16
Cho, J., Lee, J., Kim, J.-S., Kim, S. T., Lee, S., Kim, S. Y., Ha, S. Y., Park, C.-K., & Lim, H. Y. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.08.009 · Cited by 15
Townsend, M. H., Freitas, C. M. T., Larsen, D. J., Piccolo, S., Weber, K. S., Robison, R. A., & O'Neill, K. L. (2020) · Immunobiology · doi:10.1016/j.imbio.2020.151931 · Cited by 15
Poorer Prognosis With Ethylenediaminetetraacetic Acid-dependent Pseudothrombocytopenia
Ohashi-Fukuda, N., Inokuchi, R., Satō, H., Nakamura, K., Iwagami, M., Wada, T., Jona, M., Hisasue, T., Nakajima, S., & Yahagi, N. (2015) · Medicine · doi:10.1097/md.0000000000000674 · Cited by 14
Salicylate enhances the response of prostate cancer to radiotherapy
Broadfield, L. A., Marcinko, K., Tsakiridis, E. E., Zacharidis, P. G., Villani, L. A., Lally, J., Menjolian, G., Maharaj, D., Mathurin, T., Smoke, M., et al. (2019) · The Prostate · doi:10.1002/pros.23755 · Cited by 14
Non-Coding RNAs Operate in the Crosstalk Between Cancer Metabolic Reprogramming and Metastasis
Li, Z., & Sun, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00810 · Cited by 14
The effect of L-2-amino-4-methoxy-trans-3-butenoic acid on serine hydroxymethyl transferase
Tisdale, M. J. (1981) · Chemico-Biological Interactions · doi:10.1016/0009-2797(81)90092-2 · Cited by 6
Mechanism and application of nonessential amino acid deprivation associated with tumor therapy
Nong, S., Qian, Y., Zhang, T., Zhou, X., Wei, Y., Yin, X., & Ma, X. (2022) · MedComm – Future Medicine · doi:10.1002/mef2.12 · Cited by 6
Self-citation
Cited by
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534
Keoh, L. Q., Chiu, C.-F., & Ramasamy, T. S. (2025) · Stem Cell Reviews and Reports · doi:10.1007/s12015-025-10956-y · Cited by 66
He, J., Xue, W., & Li, Y. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s560983 · Cited by 16
Metadata
- Authors
- Nong, S., Han, X., Xiang, Y., Qian, Y., Wei, Y., Zhang, T., Tian, K., Shen, K., Yang, J., & Ma, X.
- Venue
- MedComm
- Publisher
- Wiley
- Published
- 2023-03-27
- Volume
- 4
- Issue
- 2
- Pages
- e218-e218
- ISSN
- 2688-2663 (ISSN-L)
- OpenAlex
- W4361006739
- Cited by
- 287
- References
- 294
- FWCI
- 27.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.